Amplia Therapeutics

Shareholder Update - July 2021

Amplia Therapeutics Limited

Amplia
Exposing cancer. Enhancing treatment.

Disclaimer

The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited ("Amplia") in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as "may", "should", "will", "expect", "anticipate", "believe", "estimate", "intend", "scheduled" or "continue" or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia's acquired product pipeline. Actual results from clinical trials may vary from those shown.

Focal Adhesion Kinase – one drug target, two applications



Focal Adhesion Kinase (FAK)

	FIBROTIC DISEASES	SOLID CANCERS
Indication		
Biology	• Collagen accumulation • Collagen crosslinking • Fibronectin production	• Cell migration and metastasis • Collagen accumulation • Local regulation of immune response
Opportunities	**Monotherapy** • Lung fibrosis • Liver fibrosis	**Combination Therapy** • Pancreatic cancer • Ovarian cancer

Amplia's target indications

Pancreatic Cancer

- 60,000 new diagnosis and 48,000 deaths from pancreatic cancer in the US each year
- Difficult-to-treat cancer that is often detected late and surrounded by a protective, fibrotic layer
- Less than 20% patients eligible for surgery – chemo main treatment
- Median survival time for patients with advanced disease is 8-9 months

AMP945 was awarded Orphan Drug Designation by the US FDA for use in treating Pancreatic Cancer in March 2020

Idiopathic Pulmonary Fibrosis (IPF)

- Affects 130,000 in the US and ~3M people worldwide
- Devastating, progressive disease caused by the build up of fibrotic tissue in the lungs
- Only two drugs approved which slow progression but are unable to stop the disease
- Median survival time is 3-5 years with current treatments

AMP945 was awarded Orphan Drug Designation by the US FDA for use in treating Idiopathic Lung Fibrosis in May 2020

Amplia's pipeline

DRUG	INDICATION	THERAPY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3 & APPROVAL
AMP945	*Pancreatic cancer*	Combination therapy				
AMP945	*Idiopathic pulmonary fibrosis (IPF)*	Monotherapy				
AMP945	*Other cancers & fibrotic diseases*	Combo/Mono therapies				
AMP886	*Cancers & fibrotic disease*	Combo/Mono therapies				

Amplia – highlights from the June 2021 quarter

- Finalised and executed Collaboration Agreement with the Garvan Institute for Medical Research in Sydney
- Preclinical data supports advancing AMP945 in Phase 2 clinical trials in patients with pancreatic cancer:
  - Inhibits formation of new fibrotic tissues
  - 27% survival benefit in aggressive model of pancreatic cancer
- Completion of successful Phase 1 clinical trial of AMP945 in healthy volunteers
  - On time and on budget
- Raised $3.8M to support preparation for initiation of Phase 2 clinical programs in pancreatic cancer and pulmonary fibrosis

Garvan Collaboration

Amplia
Exposing cancer. Enhancing treatment.

Amplia's collaboration with the Garvan Institute

- Garvan and Amplia collaboration agreement signed June 2021:
  - Prof. Timpson's group studying FAK in pancreatic cancer for >6 years
  - Professor Timpson joined Amplia's Scientific Advisory Board in Feb 2020
  - Collaboration builds on existing knowledge and taps clinician network
- Collaboration has already provided valuable data showing that AMP945:
  - Inhibits deposition and maturation of collagen that forms fibrotic tissue
  - Improves survival in an aggressive animal model of pancreatic cancer by 27% in combination with standard chemotherapies
- Further studies planned or underway

Garvan collaboration

- Amplia receives
  - Access to Garvan know-how
  - First right to arising IP
- Garvan receives
  - Research funding
  - Translational opportunities for science
- Amplia collaboration promoted in Garvan's June Seminar *The Power of Personalized Medicine*



Preclinical Data

Amplia
Exposing cancer. Enhancing treatment.

AMP945 inhibits deposition of collagen

Picosirius red staining for total collagen





- Fibroblasts lay down new collagen
- Collagen is a key component of fibrotic tissue
- AMP945 inhibits fibroblasts, causing less new collagen to be deposited

Studies conducted in the laboratory of Professor Paul Timpson (Garvan)

AMP945 has positive impact on key tumour markers

AMP945 priming strategy – pretreatment to make tumours more responsive to standard of care



Marker of cell death increases (Caspase 3)



Marker of cell proliferation decreases (Ki67)



* P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 ****P ≤ 0.0001

AMP945 improves survival in pancreatic cancer model

- 25% improvement in median survival when added to standard of care ($p \leq 0.001$)
- KPC is a highly aggressive animal model of human pancreatic cancer
- Demonstrates pharmaceutical activity of AMP945 translates into survival benefit



"A 25% improvement in survival in this model is very impressive and a level of improvement that we rarely see"

PROFESSOR PAUL TIMPSON

Phase 1 Clinical Trial

Amplia
Exposing cancer. Enhancing treatment.

Phase 1 trial of AMP945 – design and execution



Data from successful Phase 1 clinical trial of AMP945

Data on AMP945 from Phase 1 clinical trial

- Safe and well-tolerated at all doses tested:
  - Single ascending doses – up to 125mg
  - Multiple ascending dose (up to 100mg for 7 days)
- No serious adverse events (SAEs) or withdrawals and no identified safety trends
- Once-a-day oral dose supported by pharmacokinetics
- No detectable food effect – simplifies dosing
- Achieved blood levels of AMP945 sufficient to inhibit FAK

Inhibitory concentration of AMP945 achieved

- Concentrations of AMP945 that inhibit FAK were rapidly achieved in the blood of human volunteers
- These levels were maintained in the steady state concentrations achieved following oral administration of AMP945 once daily for seven days



Significance of Phase 1 results



Raised $3.8M to support preparation for Phase 2

- In May 2021, Amplia successfully completed a $3.8M capital raising at $0.23 / share
  - Total of 16.6M new shares issued
  - New institutional shareholder: Acorn Capital
  - Supported by existing institutional shareholders: Platinum and Blueflag
- New capital allows Amplia to plan and prepare its Phase 2 program for AMP945
  - Design and refine clinical trial to test AMP945 in combination with existing treatments in pancreatic cancer patients
    - Could AMP945 augment the activity of current treatment?
  - Commence preparations for Phase 2 studies
    - Prepare for IND Q1 2022
    - Manufacture of AMP945 for further clinical trials and toxicology studies
    - Longer duration animal toxicology studies to support chronic dosing in fibrosis patients



Summary

Outcomes for the quarter

- Phase 1 completion
  - Successful implementation of clinical strategy so-far
  - Opens up opportunities in cancer and fibrosis
- Garvan Collaboration
  - Supports current plans
  - Prospects for further opportunities

Coming Up

- Disclosure of pancreatic cancer trial design
- Regulatory interactions
- Updates on non-clinical studies at Garvan and elsewhere

Amplia

Exposing cancer. Enhancing treatment.

ampliatx.com